EXPIRED
PA-18-591 - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
National Center for Advancing Translational Sciences (NCATS)
The National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the need for projects that address the coronavirus disease 2019 (COVID-19) Public Health Emergency. The Clinical and Translational Science Award (CTSA) Program is uniquely qualified to contribute to these efforts. NCATS is soliciting applications for Administrative Supplements (through PA-18-591) from current Clinical and Translational Science Award (CTSA) UL1 and U24 award recipients as follows:
FOA |
Responsive Activity |
Expected Number of Awards |
RFA-TR-17-006 CTSA Program Data to Health (CD2H) Coordinating Center (U24) |
Digital health platforms and models that integrate data, assess risk, and provide illness/infection surveillance, management tools, and inform clinical practice |
1 |
RFA-TR-15-002 CTSA Network - Trial Innovation Centers (TICs) (U24) RFA-TR-15-004 Clinical and Translational Science Award (CTSA) Network Recruitment Innovation Centers (RICs) (U24) |
Planning of COVID-19 trials; additional recruitment and retention support; eConsent support; and provision of a platform and statistical expertise to collect and perform meta-analyses of COVID-19 therapeutic trials; collection and analysis of COVID-19 health records |
1-2 |
UL1 Components Only PAR-18-940 Clinical and Translational Science Award (U54 Clinical Trial Optional) PAR-18-464 Clinical and Translational Science Award (U54 Clinical Trial Optional) PAR-15-304 Clinical and Translational Science Award (U54 Clinical Trial Optional) RFA-TR-14-009 Clinical and Translational Science Award (U54 Clinical Trial Optional) |
Support of the NCATS National COVID Cohort Collaborative (N3C): Provision of clinical data in specified formats to support illness/infection status/surveillance determinations and/or clinical study data (awards anticipated to be $50,000 to $100,000 Total Costs) |
5-10 |
Use of informatics solutions to diagnose cases |
1-5 |
|
Use of CTSA-supported core resources (e.g., advanced scientific instruments, highly-specialized facilities, and regulatory expertise) to facilitate research on COVID-19 and advance the translation of research findings into diagnostics, therapeutics, and vaccines |
1-5 |
Applicants are encouraged to:
Application and Submission Information
Applications in response to this NOSI must be submitted using the following target opportunity or subsequently reissued equivalents through the expiration date of this notice. Designate “NOT-TR-20-029” (without quotation marks) in the Agency Routing Identifier field (Box 4b) of the SF424 (R&R) Form as directed below.
When developing applications in response to this NOSI, all instructions in the SF424 (R&R) Application Guide and in the target funding opportunity announcement (PA-18-591) must be followed, with the following additions:
Investigators planning to submit an application in response to this NOSI are strongly encouraged to contact the Grants Management Specialist on their active award to determine eligibility and the Program Officer on their active award to discuss the proposed project in the context of the parent award.
Applications that do not meet the requirements specified in this NOSI will be withdrawn from consideration for this initiative.
Scientific/Research Contact(s)
Please contact the program officer on your active award.